Abstract
The neuropathological signs of Alzheimer’s disease (AD) include beta amyloid plaques and neurofibrillary tangles. There is a significant population of individuals that have these key hallmarks but show no signs of cognitive impairment, termed non-demented with AD neuropathology (NDAN). The protective mechanism allowing these individuals to escape dementia is unknown. Serum amyloid P (SAP) is a serum protein associated with wound repair that is elevated in the brains of Alzheimer’s patients and binds to amyloid plaques. Using immunoblotting and immunohistochemistry, we evaluated SAP levels in postmortem samples of hippocampus and frontal cortex in age-matched controls, AD, and NDAN individuals. AD individuals had significantly increased SAP levels compared to normal controls, while NDAN samples had no significant difference in SAP levels compared to normal controls. Our results suggest that low levels of SAP in plaques marks the brains of individuals that escape dementia despite the presence of beta amyloid plaques and tangles.
Similar content being viewed by others
References
Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362(4):329–344. doi:10.1056/NEJMra0909142
Guillozet AL, Weintraub S, Mash DC, Mesulam MM (2003) Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 60(5):729–736. doi:10.1001/archneur.60.5.729
Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66(12):1837–1844. doi:10.1212/01.wnl.0000219668.47116.e6
Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65(11):1509–1517. doi:10.1001/archneur.65.11.1509
Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc Natl Acad Sci USA 106(16):6820–6825. doi:10.1073/pnas.0900345106
Pepys MB, Baltz ML (1983) Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34:141–212
Thompson D, Pepys MB, Tickle I, Wood S (2002) The structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose. J Mol Biol 320(5):1081–1086
Yasojima K, Schwab C, McGeer EG, McGeer PL (2000) Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease. Brain Res 887(1):80–89
Kimura M, Asada T, Uno M, Machida N, Kasuya K, Taniguchi Y, Fujita T, Nishiyama E, Iwamoto N, Arai H (1999) Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer’s disease. Neurosci Lett 273(2):137–139
Mulder C, Schoonenboom SN, Wahlund LO, Scheltens P, van Kamp GJ, Veerhuis R, Hack CE, Blomberg M, Schutgens RB, Eikelenboom P (2002) CSF markers related to pathogenetic mechanisms in Alzheimer’s disease. J Neural Transm 109(12):1491–1498. doi:10.1007/s00702-002-0763-y
Verwey NA, Schuitemaker A, van der Flier WM, Mulder SD, Mulder C, Hack CE, Scheltens P, Blankenstein MA, Veerhuis R (2008) Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer’s disease. Dement Geriatr Cogn Disord 26(6):522–527. doi:10.1159/000178756
Emsley J, White HE, O’Hara BP, Oliva G, Srinivasan N, Tickle IJ, Blundell TL, Pepys MB, Wood SP (1994) Structure of pentameric human serum amyloid P component. Nature 367(6461):338–345. doi:10.1038/367338a0
Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E (1997) Amyloid P component. A critical review. Amyloid 4:274–295
Naik-Mathuria B, Pilling D, Crawford JR, Gay AN, Smith CW, Gomer RH, Olutoye OO (2008) Serum amyloid P inhibits dermal wound healing. Wound Repair Regen 16(2):266–273. doi:10.1111/j.1524-475X.2008.00366.x
Agrawal A, Singh PP, Bottazzi B, Garlanda C, Mantovani A (2009) Pattern recognition by pentraxins. Adv Exp Med Biol 653:98–116
Gomer RH, Pilling D, Kauvar LM, Ellsworth S, Ronkainen SD, Roife D, Davis SC (2009) A serum amyloid P-binding hydrogel speeds healing of partial thickness wounds in pigs. Wound Repair Regen 17(3):397–404. doi:10.1111/j.1524-475X.2009.00482.x
Pilling D, Roife D, Wang M, Ronkainen SD, Crawford JR, Travis EL, Gomer RH (2007) Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 179(6):4035–4044. doi:179/6/4035[pii]
Castano AP, Lin SL, Surowy T, Nowlin BT, Turlapati SA, Patel T, Singh A, Li S, Lupher ML, Jr., Duffield JS (2009) Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 1 (5):5ra13. doi:10.1126/scitranslmed.3000111
Moreira AP, Cavassani KA, Hullinger R, Rosada RS, Fong DJ, Murray L, Hesson DP, Hogaboam CM (2010) Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J Allerg Clin Immunol 126(4):712–721. doi:10.1016/j.jaci.2010.06.010 e717
Murray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, Peng X, Gulati M, Homer RJ, Russell T, van Rooijen N, Elias JA, Hogaboam CM, Herzog EL (2011) TGF-beta driven lung fibrosis is macrophage dependent and blocked by serum amyloid P. Int J Biochem Cell Biol 43(1):154–162. doi:10.1016/j.biocel.2010.10.013
Murray LA, Kramer MS, Hesson DP, Watkins BA, Fey EG, Argentieri RL, Shaheen F, Knight DA, Sonis ST (2010) Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis. Fibrogenesis Tissue Repair 3:11. doi:10.1186/1755-1536-3-11
Coria F, Castano E, Prelli F, Larrondo-Lillo M, van Duinen S, Shelanski ML, Frangione B (1988) Isolation and characterization of amyloid P component from Alzheimer’s disease and other types of cerebral amyloidosis. Lab Invest 58(4):454–458
Kalaria RN, Grahovac I (1990) Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: implications for leakage across the blood-brain barrier in Alzheimer’s disease. Brain Res 516(2):349–353
McGeer EG, Yasojima K, Schwab C, McGeer PL (2001) The pentraxins: possible role in Alzheimer’s disease and other innate inflammatory diseases. Neurobiol Aging 22(6):843–848
Urbanyi Z, Laszlo L, Tomasi TB, Toth E, Mekes E, Sass M, Pazmany T (2003) Serum amyloid P component induces neuronal apoptosis and beta-amyloid immunoreactivity. Brain Res 988(1–2):69–77
Urbanyi Z, Sass M, Laszy J, Takacs V, Gyertyan I, Pazmany T (2007) Serum amyloid P component induces TUNEL-positive nuclei in rat brain after intrahippocampal administration. Brain Res 1145:221–226. doi:10.1016/j.brainres.2007.01.132
Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 92(10):4299–4303
Janciauskiene S, Garcia de Frutos P, Carlemalm E, Dahlback B, Eriksson S (1995) Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. J Biol Chem 270(44):26041–26044
Pepys MB (2006) Amyloidosis. Annu Rev Med 57:223–241. doi:10.1146/annurev.med.57.121304.131243
Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 3(8):855–859
Togashi S, Lim SK, Kawano H, Ito S, Ishihara T, Okada Y, Nakano S, Kinoshita T, Horie K, Episkopou V, Gottesman ME, Costantini F, Shimada K, Maeda S (1997) Serum amyloid P component enhances induction of murine amyloidosis. Lab Invest 77(5):525–531
Pilling D, Buckley CD, Salmon M, Gomer RH (2003) Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 17(10):5537–5546
Romijn HJ, van Uum JF, Breedijk I, Emmering J, Radu I, Pool CW (1999) Double immunolabeling of neuropeptides in the human hypothalamus as analyzed by confocal laser scanning fluorescence microscopy. J Histochem Cytochem 47(2):229–236
Edelstein A, Amodaj N, Hoover K, Vale R, Stuurman N (2010) Computer control of microscopes using microManager. Curr Protoc Mol Biol Chapter 14:Unit14 20. doi:10.1002/0471142727.mb1420s92
Duong T, Pommier EC, Scheibel AB (1989) Immunodetection of the amyloid P component in Alzheimer’s disease. Acta Neuropathol 78(4):429–437
Lee YJ, Han SB, Nam SY, Oh KW, Hong JT (2010) Inflammation and Alzheimer’s disease. Arch Pharm Res 33(10):1539–1556. doi:10.1007/s12272-010-1006-7
Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH (1994) Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex 4(2):138–150
Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417(6886):254–259
Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB (2009) Molecular dissection of Alzheimer’s disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci USA 106(18):7619–7623. doi:10.1073/pnas.0902640106
Acknowledgments
We thank Dr. Randy Woltjer at Oregon Health and Science University, Portland, OR, for providing the tissue used in these studies and standard neuropathological assessment of the cases.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Crawford, J.R., Bjorklund, N.L., Taglialatela, G. et al. Brain Serum Amyloid P Levels are Reduced in Individuals that Lack Dementia While Having Alzheimer’s Disease Neuropathology. Neurochem Res 37, 795–801 (2012). https://doi.org/10.1007/s11064-011-0674-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-011-0674-0